MCID: PLY011
MIFTS: 65

Polycystic Ovary Syndrome

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 37 12 24 36 51 40 41 14 69
Polycystic Ovarian Syndrome 72 49 24
Polycystic Ovaries 12 28 51
Pcos 12 49 24
Polycystic Ovarian Disease 12 24
Stein-Leventhal Syndrome 12 24
Sclerocystic Ovaries 24 69
Multicystic Ovaries 12 24
Sclerocystic Ovarian Degeneration 24
Sclerocystic Ovary Syndrome 24
Cystic Disease of Ovaries 24
Cystic Disease of Ovary 24
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Pcod 24
Pco 24

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
ICD10 32 E28.2
ICD9CM 34 256.4
MeSH 41 D011085
NCIt 46 C26862
KEGG 36 H01739

Summaries for Polycystic Ovary Syndrome

MedlinePlus : 40 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to aromatase deficiency and acanthosis nigricans, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is PCOS1 (Polycystic Ovary Syndrome 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Prolactin Signaling Pathway. The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Genetics Home Reference : 24 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.

NIH Rare Diseases : 49 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne. Last updated: 6/7/2016

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 225, show less)
# Related Disease Score Top Affiliating Genes
1 aromatase deficiency 32.7 CYP19A1 GNRH1 INS
2 acanthosis nigricans 31.0 INS INSR LEP SHBG
3 infertility 30.9 CYP19A1 FSHR GNRH1 PRL
4 hyperprolactinemia 30.7 GNRH1 IGF1 PRL
5 sleep apnea 30.7 IGF1 INS LEP
6 central precocious puberty 30.6 GNRH1 IGF1 LEP
7 androgenic alopecia 30.6 CYP19A1 PRL SHBG
8 glucose intolerance 30.5 IGF1 IGFBP1 INS INSR LEP SHBG
9 gestational diabetes 30.5 CAPN10 INS INSR LEP SHBG
10 hyperglycemia 30.5 IGF1 INS INSR LEP
11 ovarian hyperstimulation syndrome 30.5 CYP19A1 FSHR GNRH1
12 breast disease 30.5 IGF1 PRL SHBG
13 amenorrhea 30.4 FSHR GNRH1 LEP PRL SHBG
14 ovarian disease 30.4 CYP11A1 CYP19A1 FSHR GDF9 GNRH1 IGF1
15 diabetes mellitus 30.4 CAPN10 IGF1 INS INSR LEP SHBG
16 hyperinsulinism 30.4 IGF1 IGFBP1 INS INSR LEP SHBG
17 hyperandrogenism 30.3 CYP17A1 CYP19A1 CYP21A2 GNRH1 HSD3B2 IGF1
18 precocious puberty 30.2 CYP19A1 CYP21A2 GNRH1
19 insulin-like growth factor i 30.2 IGF1 IGFBP1 INS INSR LEP PRL
20 estrogen excess 30.2 CYP19A1 FSHR SHBG
21 myoma 30.1 CYP19A1 GNRH1 LEP
22 anovulation 30.1 CYP19A1 FSHR GNRH1 IGF1 INS LEP
23 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 30.0 CYP21A2 LEP
24 transsexualism 30.0 CYP17A1 CYP19A1 CYP21A2
25 acromegaly 29.9 IGF1 IGFBP1 INS PRL
26 cortisone reductase deficiency 29.9 CYP21A2 H6PD HSD11B1
27 3-beta-hydroxysteroid dehydrogenase deficiency 29.9 CYP21A2 HSD3B2
28 body mass index quantitative trait locus 11 29.7 CAPN10 CYP21A2 H6PD HSD11B1 IGF1 IGFBP1
29 endometrial cancer 29.5 CYP19A1 GNRH1 IGF1 IGFBP1 INS SHBG
30 premature ovarian failure 1 29.5 CYP11A1 CYP19A1 FSHR GDF9 GNRH1 PRL
31 lipoid congenital adrenal hyperplasia 29.3 CYP11A1 CYP17A1 CYP21A2 HSD3B2
32 polycystic ovary syndrome 1 12.3
33 cortisone reductase deficiency 1 11.4
34 acth-independent macronodular adrenal hyperplasia 11.0
35 ovarian cyst 11.0
36 hair-an syndrome 11.0
37 body mass index quantitative trait locus 9 10.9
38 body mass index quantitative trait locus 8 10.9
39 body mass index quantitative trait locus 7 10.9
40 body mass index quantitative trait locus 12 10.9
41 body mass index quantitative trait locus 14 10.9
42 body mass index quantitative trait locus 18 10.9
43 body mass index quantitative trait locus 4 10.9
44 body mass index quantitative trait locus 10 10.9
45 insulin autoimmune syndrome 10.7 INS INSR
46 hyperandrogenism due to cortisone reductase deficiency 10.6 H6PD HSD11B1
47 secondary adrenal insufficiency 10.6 IGF1 INS
48 abdominal obesity-metabolic syndrome 1 10.6 HSD11B1 INS LEP
49 hypoactive sexual desire disorder 10.6 CYP19A1 SHBG
50 galactorrhea 10.6 IGF1 PRL
51 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.5 IGF1 INS INSR
52 sheehan syndrome 10.5 IGF1 INS PRL
53 lipodystrophy, familial partial, type 2 10.5 INS LEP
54 oocyte maturation defect 1 10.5 CYP19A1 FST
55 hyperpituitarism 10.5 IGF1 INS PRL
56 donohue syndrome 10.5 IGF1 INS INSR
57 endocrine pancreas disease 10.5 IGF1 INS LEP
58 pancreas disease 10.5 IGF1 INS LEP
59 thyroid gland disease 10.5 IGF1 INS PRL
60 body mass index quantitative trait locus 1 10.5
61 pseudohypoparathyroidism, type ia 10.5 IGF1 PRL
62 cell type benign neoplasm 10.5 IGF1 INS PRL
63 gynecomastia 10.5 CYP19A1 PRL SHBG
64 pituitary apoplexy 10.5 GNRH1 INS PRL
65 endotheliitis 10.5
66 empty sella syndrome 10.5 GNRH1 INS PRL
67 lutheran suppressor, x-linked 10.4 HSD11B1 INS INSR LEP
68 endometriosis of uterus 10.4 GNRH1 PRL
69 premenstrual tension 10.4 GNRH1 PRL SHBG
70 chromophobe adenoma 10.4 GNRH1 INS PRL
71 hyperthyroidism 10.4 INS LEP PRL SHBG
72 mccune-albright syndrome 10.4 CYP19A1 IGF1 PRL
73 bulimia nervosa 2 10.4 IGF1 LEP PRL
74 glucose metabolism disease 10.4 IGF1 INS LEP
75 hypogonadotropism 10.4 GNRH1 PRL
76 pituitary infarct 10.4 GNRH1 IGF1 PRL
77 aging 10.4
78 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 INS LEP
79 hyperproinsulinemia 10.4 IGFBP1 INS SHBG
80 pituitary adenoma 1, multiple types 10.4 IGF1 PRL
81 varicocele 10.4 GNRH1 PRL SHBG
82 fetal macrosomia 10.4 IGF1 INS INSR LEP
83 androgen insensitivity, partial 10.4 CYP19A1 SHBG
84 hypothalamic disease 10.4 GNRH1 PRL
85 precocious puberty, male-limited 10.4 CYP19A1 FSHR
86 chiasmal syndrome 10.4 GNRH1 PRL
87 overnutrition 10.3 HSD11B1 IGF1 INS LEP SHBG
88 pituitary gland disease 10.3 GNRH1 IGF1 INS PRL
89 craniopharyngioma 10.3 GNRH1 IGF1 INS PRL
90 cryptorchidism, unilateral or bilateral 10.3 CYP19A1 GNRH1 SHBG
91 hypopituitarism 10.3 GNRH1 IGF1 INS PRL
92 acquired metabolic disease 10.3 IGF1 INS LEP PRL SHBG
93 mammographic density 10.3 CYP17A1 CYP19A1 IGF1 PRL
94 pseudohermaphroditism 10.3 CYP17A1 CYP19A1 HSD3B2
95 turner syndrome 10.3 IGF1 IGFBP1 SHBG
96 thyroiditis 10.3
97 nutritional deficiency disease 10.3 IGF1 IGFBP1 LEP
98 prostatic adenoma 10.2 PRL SHBG
99 male reproductive organ cancer 10.2 CYP17A1 GNRH1 IGF1 SHBG
100 alopecia, androgenetic, 1 10.2 CYP19A1 CYP21A2 SHBG
101 leiomyoma, uterine 10.2 CYP17A1 CYP19A1 GNRH1 IGF1
102 type 1 diabetes mellitus 7 10.2 IGFBP1 INS
103 adrenal gland hyperfunction 10.2 CYP21A2 LEP PRL
104 inherited metabolic disorder 10.2 CYP21A2 INS LEP
105 liver disease 10.2
106 fatty liver disease 10.2
107 cytochrome p450 oxidoreductase deficiency 10.1 CYP17A1 CYP21A2
108 diabetes mellitus, insulin-dependent 10.1 IGF1 IGFBP1 INS LEP
109 blood group, i system 10.1
110 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
111 luteoma 10.1 CYP19A1 CYP21A2
112 antley-bixler syndrome 10.1 CYP17A1 CYP19A1 CYP21A2
113 hepatitis 10.1
114 hypothyroidism 10.1
115 autonomic dysfunction 10.1
116 gonadal disease 10.1 FSHR GNRH1 IGF1 INS SHBG
117 hashimoto thyroiditis 10.0
118 fatty liver disease, nonalcoholic 1 10.0
119 acute adrenal insufficiency 10.0 CYP11A1 CYP21A2
120 prader-willi syndrome 10.0 GNRH1 IGF1 IGFBP1 INS LEP
121 anxiety 10.0
122 borderline personality disorder 10.0
123 prostatitis 10.0
124 personality disorder 10.0
125 intracranial hypertension 10.0
126 nonalcoholic steatohepatitis 10.0
127 adrenal rest tumor 10.0 CYP21A2 GNRH1 HSD3B2
128 hypospadias 10.0 CYP11A1 CYP17A1 HSD3B2
129 penis agenesis 9.9 CYP17A1 GNRH1
130 testicular leydig cell tumor 9.9 CYP11A1 CYP17A1 CYP21A2
131 apnea, obstructive sleep 9.9
132 arteries, anomalies of 9.9
133 fibrosis of extraocular muscles, congenital, 1 9.9
134 hepatic adenomas, familial 9.9
135 transsexuality 9.9
136 coronary heart disease 1 9.9
137 alopecia 9.9
138 coronary artery anomaly 9.9
139 hepatocellular adenoma 9.9
140 heart disease 9.9
141 goiter 9.9
142 graves' disease 9.9
143 nodular goiter 9.9
144 vascular disease 9.9
145 cervicitis 9.9
146 gingivitis 9.9
147 pancreatitis 9.9
148 adenoma 9.9
149 lipodystrophy 9.9
150 idiopathic central precocious puberty 9.9
151 pituitary-dependent cushing's disease 9.9 CYP21A2 GNRH1 HSD11B1 INS PRL
152 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 9.9 CYP11A1 CYP17A1 CYP21A2
153 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 9.9 CYP11A1 CYP17A1 CYP21A2
154 adrenal cortical adenoma 9.9 CYP11A1 CYP17A1 CYP21A2
155 adrenal carcinoma 9.8 CYP11A1 CYP17A1 CYP21A2
156 osteoporosis 9.8 CYP19A1 FSHR HSD11B1 IGF1 INS LEP
157 adrenal adenoma 9.8 CYP11A1 CYP17A1 CYP21A2 HSD11B1
158 reproductive system disease 9.8 CYP19A1 FSHR GDF9 GNRH1 INS PRL
159 leydig cell tumor 9.7 CYP11A1 CYP17A1 CYP19A1 CYP21A2
160 blood group--diego system 9.7
161 cherubism 9.7
162 peutz-jeghers syndrome 9.7
163 thrombophilia due to thrombin defect 9.7
164 wilms tumor 1 9.7
165 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.7
166 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 9.7
167 hemochromatosis, type 1 9.7
168 intracranial hypertension, idiopathic 9.7
169 popliteal pterygium syndrome, lethal type 9.7
170 androgen insensitivity syndrome 9.7
171 helicobacter pylori infection 9.7
172 pituitary adenoma, prolactin-secreting 9.7
173 wilms tumor 5 9.7
174 acute insulin response 9.7
175 homocysteinemia 9.7
176 myelodysplastic syndrome 9.7
177 immunodeficiency 23 9.7
178 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
179 wilms tumor 6 9.7
180 multiple mitochondrial dysfunctions syndrome 5 9.7
181 morbid obesity 9.7
182 familial partial lipodystrophy 9.7
183 ectopic pregnancy 9.7
184 thrombosis 9.7
185 mucositis 9.7
186 endometrial disease 9.7
187 pre-eclampsia 9.7
188 chlamydia 9.7
189 allergic hypersensitivity disease 9.7
190 vogt-koyanagi-harada disease 9.7
191 eclampsia 9.7
192 generalized anxiety disorder 9.7
193 papilledema 9.7
194 hereditary angioedema 9.7
195 angioedema 9.7
196 vaginitis 9.7
197 thrombocytosis 9.7
198 hidradenitis suppurativa 9.7
199 hidradenitis 9.7
200 thrombophilia 9.7
201 cystadenoma 9.7
202 endometrial adenocarcinoma 9.7
203 adenocarcinoma 9.7
204 lipid metabolism disorder 9.7
205 teratoma 9.7
206 mood disorder 9.7
207 retinitis 9.7
208 pustulosis of palm and sole 9.7
209 conjunctivitis 9.7
210 eating disorder 9.7
211 psoriasis 9.7
212 hypoglycemia 9.7
213 mitochondrial disorders 9.7
214 mosaic variegated aneuploidy syndrome 9.7
215 non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 9.7
216 tetraploidy 9.7
217 trisomy 12 mosaicism 9.7
218 headache 9.7
219 refractory anemia 9.7
220 adrenocortical carcinoma, hereditary 9.7 CYP11A1 CYP17A1 CYP19A1 CYP21A2
221 steroid inherited metabolic disorder 9.7 CYP11A1 CYP17A1 CYP21A2 HSD3B2
222 conn's syndrome 9.6 CYP11A1 CYP17A1 CYP21A2
223 female reproductive system disease 9.6 CYP17A1 CYP19A1 FSHR GDF9 GNRH1 INS
224 sex differentiation disease 9.5 CYP17A1 CYP19A1 CYP21A2 GNRH1 INS PRL
225 diabetes mellitus, noninsulin-dependent 9.5 CAPN10 HSD11B1 IGF1 IGFBP1 INS INSR

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

GenomeRNAi Phenotypes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

25 (showing 23, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.78 IGF1 LEP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.78 LEP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.78 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.78 CYP21A2 IGF1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.78 INSR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.78 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.78 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.78 IGF1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.78 INSR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.78 CYP21A2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.78 SHBG
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.78 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.78 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.78 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.78 CYP21A2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.78 LEP SHBG CYP21A2 IGF1 INSR
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.78 LEP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.78 IGF1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.78 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.78 LEP
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.78 INSR
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.78 INSR
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.78 IGF1

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

43 (showing 13, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.32 INSR IGF1 GDF9 GNRH1 H6PD INS
2 homeostasis/metabolism MP:0005376 10.31 IGF1 GDF9 GNRH1 H6PD INS HSD11B1
3 growth/size/body region MP:0005378 10.27 IGF1 GNRH1 H6PD INS HSD11B1 CYP19A1
4 cellular MP:0005384 10.24 INS HSD11B1 IGF1 IGFBP1 CYP17A1 FST
5 cardiovascular system MP:0005385 10.21 INS HSD11B1 IGF1 FST CYP19A1 CAPN10
6 adipose tissue MP:0005375 10.18 IGF1 INS HSD11B1 CYP19A1 INSR CAPN10
7 immune system MP:0005387 10.18 IGF1 GNRH1 IGFBP1 INS HSD11B1 PRL
8 integument MP:0010771 10.02 INS HSD11B1 IGF1 GNRH1 FST PRL
9 liver/biliary system MP:0005370 10.02 GNRH1 IGFBP1 INS HSD11B1 PRL CYP19A1
10 muscle MP:0005369 9.91 IGF1 H6PD INS HSD11B1 CYP19A1 INSR
11 nervous system MP:0003631 9.9 INS HSD11B1 IGF1 GNRH1 FST PRL
12 renal/urinary system MP:0005367 9.56 IGF1 GNRH1 INS CYP19A1 CAPN10 INSR
13 reproductive system MP:0005389 9.4 IGF1 GDF9 GNRH1 INS PRL CYP19A1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 345, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 4091 14219
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
5
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
6
Ganirelix Approved Phase 4,Early Phase 1 124904-93-4, 123246-29-7 25081094
7
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
8
Hydrocortisone Approved, Vet_approved Phase 4,Early Phase 1 50-23-7 657311 5754
9
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
11
Menotropins Approved Phase 4,Phase 2,Phase 1 9002-68-0, 61489-71-2 5360545
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 57-83-0 5994
13
Zinc Approved, Investigational Phase 4,Early Phase 1 7440-66-6 32051 23994
14
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
15
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0 445154
16
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
17
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
18
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
19
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3 616-91-1 12035
20
Liraglutide Approved Phase 4 204656-20-2 44147092
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Epinephrine Approved, Vet_approved Phase 4,Early Phase 1 51-43-4 5816
23 Racepinephrine Approved Phase 4,Early Phase 1 329-65-7
24
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
25
Leuprolide Approved, Investigational Phase 4,Phase 2,Early Phase 1 53714-56-0 657181 3911
26
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
27
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
28
Alogliptin Approved Phase 4 850649-61-5 11450633
29
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
30
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
31
Tamoxifen Approved Phase 4 10540-29-1 2733526
32
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
33
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
34
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 77-92-9 311
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
39
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 10883523 5280795 6221
40
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
42
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
43
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
45
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
46
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
47
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
48
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
49
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15690-57-0
50
2,4-thiazolidinedione Investigational Phase 4,Early Phase 1 2295-31-0
51 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
52 Androgen Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
53 Androgens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
54 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
55 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
56
Cyproterone Phase 4,Phase 2,Phase 3,Early Phase 1 2098-66-0 5284537
57 Cyproterone acetate, ethinyl estradiol drug combination Phase 4,Phase 2
58 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
59 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
60 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 979-32-8
61 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
62 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
63 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
64 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
65 Antidepressive Agents Phase 4
66 Anti-Obesity Agents Phase 4,Phase 3,Phase 2
67 Appetite Depressants Phase 4,Phase 3
68 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
69 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
70 Psychotropic Drugs Phase 4
71 Clomiphene Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
72 Zuclomiphene Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
73 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
74 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
75 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
76 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
77 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
78 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
79 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
80 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
81 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
82 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
83 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
84 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
85 Contraceptives, Oral Phase 4,Phase 2,Phase 3
86 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
87 Deslorelin Phase 4,Phase 3
88 Luteolytic Agents Phase 4,Phase 3
89 Triptorelin Pamoate Phase 4,Phase 3
90 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
91 Contraceptives, Oral, Combined Phase 4,Phase 2,Phase 3
92 diuretics Phase 4,Phase 2,Phase 1,Early Phase 1
93 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 1,Early Phase 1
94 Drospirenone and ethinyl estradiol combination Phase 4,Phase 3,Phase 1
95 Hemostatics Phase 4,Phase 2
96 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
97 Mineralocorticoids Phase 4,Phase 2,Phase 1,Early Phase 1
98 Natriuretic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
99 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
100 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
101 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
102 Antimetabolites Phase 4,Phase 3,Phase 2
103 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
104 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
105 Liver Extracts Phase 4,Phase 2
106 Hematinics Phase 4,Phase 2,Phase 3,Phase 1
107 Incretins Phase 4,Phase 3,Phase 2
108 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
109 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1
110 Cortisol succinate Phase 4,Early Phase 1
111 Hydrocortisone 17-butyrate 21-propionate Phase 4,Early Phase 1
112 Hydrocortisone acetate Phase 4,Early Phase 1
113 Antiparkinson Agents Phase 4,Phase 3,Phase 2
114 Autonomic Agents Phase 4,Phase 3,Early Phase 1
115 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
116 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
117 Anticholesteremic Agents Phase 4,Phase 3,Phase 2
118 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
119 Progestins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
120 Central Nervous System Depressants Phase 4
121 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
122 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
123 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
124 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
125 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
126 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
127 Antineoplastic Agents, Phytogenic Phase 4,Phase 3
128 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
129 Platelet Aggregation Inhibitors Phase 4,Phase 3
130 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Early Phase 1
131 Antiemetics Phase 4,Phase 3,Early Phase 1
132 Thioctic Acid Phase 4,Phase 1
133
Medroxyprogesterone Phase 4,Phase 3,Phase 1 520-85-4 10631
134 Antihypertensive Agents Phase 4
135 Antidotes Phase 4,Phase 2,Phase 3
136 Antiviral Agents Phase 4,Phase 2,Phase 3
137 Expectorants Phase 4,Phase 2,Phase 3
138 N-monoacetylcystine Phase 4,Phase 2,Phase 3
139 Respiratory System Agents Phase 4,Phase 2,Phase 3,Early Phase 1
140 Nicotinic Acids Phase 4
141 Vasodilator Agents Phase 4
142 Glucagon-Like Peptide 1 Phase 4,Phase 3
143 Mitogens Phase 4,Early Phase 1
144 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
145 Antidepressive Agents, Second-Generation Phase 4
146 Cholinergic Agents Phase 4
147 Cholinergic Antagonists Phase 4
148 Epinephryl borate Phase 4,Early Phase 1
149 Muscarinic Antagonists Phase 4
150 Neurotransmitter Uptake Inhibitors Phase 4
151 Parasympatholytics Phase 4
152
Serotonin Phase 4 50-67-9 5202
153 Serotonin Agents Phase 4
154 Serotonin Uptake Inhibitors Phase 4
155 Phosphodiesterase 4 Inhibitors Phase 4
156 Phosphodiesterase Inhibitors Phase 4
157 Follicle Stimulating Hormone Phase 4,Phase 3,Early Phase 1
158 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
159 HIV Protease Inhibitors Phase 4,Phase 3,Early Phase 1
160
protease inhibitors Phase 4,Phase 3,Early Phase 1
161 Sitagliptin Phosphate Phase 4
162 Phytoestrogens Phase 4
163 Vitamin B 12 Phase 4
164 Dermatologic Agents Phase 4
165 Cardiac Glycosides Phase 4
166 Glycoside Hydrolase Inhibitors Phase 4
167 glucocorticoids Phase 4,Phase 3,Early Phase 1
168 Dacuronium Phase 4
169 Tin Fluorides Phase 4
170 glucagon Phase 4,Phase 3
171 Methylprednisolone acetate Phase 4
172 Methylprednisolone Hemisuccinate Phase 4
173 Neuroprotective Agents Phase 4,Phase 3
174 Prednisolone acetate Phase 4
175 Prednisolone hemisuccinate Phase 4
176 Prednisolone phosphate Phase 4
177 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
178 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
179 Inositol Nutraceutical Phase 4,Phase 2,Phase 3,Early Phase 1
180 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
181 carnitine Nutraceutical Phase 4
182 Calciferol Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
183 Vitamin D2 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
184 Alpha-lipoic Acid Nutraceutical Phase 4,Phase 1
185 cysteine Nutraceutical Phase 4,Phase 2,Phase 3
186 Vitamin B3 Nutraceutical Phase 4
187 Olive Nutraceutical Phase 4
188
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
189 Vitamin B12 Nutraceutical Phase 4
190 Acidophilus Nutraceutical Phase 4
191 Bifidobacterium Nutraceutical Phase 4
192
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
193
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
194
Cetrorelix Approved, Investigational Phase 3,Phase 2 120287-85-6 25074887 16129715
195
Chromium Approved Phase 3 7440-47-3 27668
196
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Early Phase 1 50-02-2 5743
197
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
198
Saxagliptin Approved Phase 3 361442-04-8 11243969
199
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
200
Empagliflozin Approved Phase 2, Phase 3 864070-44-0
201
Phentermine Approved, Illicit Phase 3 122-09-8 4771
202
Topiramate Approved Phase 3 97240-79-4 5284627
203 Cinnamon Approved, Nutraceutical Phase 3,Phase 1
204 tannic acid Approved, Nutraceutical Phase 3,Phase 2
205
Lactitol Investigational Phase 3 585-86-4 3871
206 Dopamine Agents Phase 3,Phase 2
207 Dopamine agonists Phase 3,Phase 2
208 Hydroxycholecalciferols Phase 3,Phase 2
209 Prolactin Release-Inhibiting Factors Phase 3
210 Calcifediol Phase 3 19356-17-3
211 Raloxifene Hydrochloride Phase 3
212 BB 1101 Phase 3,Early Phase 1
213 Dexamethasone acetate Phase 3,Early Phase 1 1177-87-3
214 Anti-Bacterial Agents Phase 3
215 Antibiotics, Antitubercular Phase 3
216 Antimalarials Phase 3
217 Antiparasitic Agents Phase 3
218 Antiprotozoal Agents Phase 3
219 Matrix Metalloproteinase Inhibitors Phase 3
220 Anesthetics Phase 2, Phase 3
221
s 1 (combination) Phase 3
222 Gonadotropins, Pituitary Phase 3
223 Adrenergic Agents Phase 3,Early Phase 1
224 Anticonvulsants Phase 3
225 Central Nervous System Stimulants Phase 3
226 Calcium Supplement Nutraceutical Phase 3
227
Norethindrone Approved Phase 2 68-22-4 6230